Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.35 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.35 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 5/20 | 0.34 |
| ▸ | CTSH | P09668 | 4/20 | 0.34 |
| ▸ | CTSK | P43235 | 4/20 | 0.34 |
| ▸ | CTSL | P07711 | 3/20 | 0.34 |
| ▸ | CTSS | P25774 | 3/20 | 0.34 |
| ▸ | CTSF | Q9UBX1 | 2/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | CTSV | O60911 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22493536 | 1.00 | ITGB3 (0.38) | ITGB3ITGA2BKLKB1ERAP2LNPEP | |
| SCHEMBL299855 | 0.74 | ITGB3 (0.43) | ITGB3ITGA2BCTSKCTSS | |
| SCHEMBL25661167 | 0.74 | CTSB (0.56) | ITGB3ITGA2BCTSBCTSHCTSK | |
| SCHEMBL22511372 | 0.73 | PRCP (0.35) | — | |
| SCHEMBL22493569 | 0.73 | PRCP (0.35) | — | |
| SCHEMBL6308179 | 0.71 | GSR (0.38) | — | |
| SCHEMBL15148580 | 0.71 | ERAP2 (0.43) | ITGB3ITGA2BERAP2LNPEPERAP1 | |
| SCHEMBL634032 | 0.71 | FOLH1 (0.46) | ERAP2LNPEPERAP1CNR2ANPEP | |
| SCHEMBL2387748 | 0.71 | SIRT6 (0.54) | ITGB3ITGA2BERAP2LNPEPERAP1 | |
| SCHEMBL5494276 | 0.71 | SIRT6 (0.54) | ITGB3ITGA2BERAP2LNPEPERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200317723-A1 | Bioconjugation of Polypeptides | THE UNIVERSITY OF YORK (GB) | 2020-10-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317723-A1 | Bioconjugation of Polypeptides | PTMS, EPCAM, IAPP | ITGB3 918/4885ITGA2B 2313/4885KLKB1 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.